JP2024513988A - Ｌｔａ４ｈの阻害剤としてのヘテロアリールアミノプロパノール誘導体 - Google Patents

Ｌｔａ４ｈの阻害剤としてのヘテロアリールアミノプロパノール誘導体 Download PDF

Info

Publication number
JP2024513988A
JP2024513988A JP2023562998A JP2023562998A JP2024513988A JP 2024513988 A JP2024513988 A JP 2024513988A JP 2023562998 A JP2023562998 A JP 2023562998A JP 2023562998 A JP2023562998 A JP 2023562998A JP 2024513988 A JP2024513988 A JP 2024513988A
Authority
JP
Japan
Prior art keywords
oxy
phenyl
amino
mmol
propan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513988A5 (https=
Inventor
コルディコウスキー，アンドレアス
リウ，ユガン
マーティン ロンド，レイナー
マーカート，クリスチャン
ミルツ，ウォルフガング
レーン，ティル
スパンカ，カーステン
トーマ，ゲプハルト
シェ，ティエン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024513988A publication Critical patent/JP2024513988A/ja
Publication of JP2024513988A5 publication Critical patent/JP2024513988A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023562998A 2021-04-16 2022-04-13 Ｌｔａ４ｈの阻害剤としてのヘテロアリールアミノプロパノール誘導体 Pending JP2024513988A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/087655 2021-04-16
CN2021087655 2021-04-16
US202263311231P 2022-02-17 2022-02-17
US63/311,231 2022-02-17
PCT/IB2022/053454 WO2022219546A1 (en) 2021-04-16 2022-04-13 Heteroaryl aminopropanol derivatives as inhibitors of lta4h

Publications (2)

Publication Number Publication Date
JP2024513988A true JP2024513988A (ja) 2024-03-27
JP2024513988A5 JP2024513988A5 (https=) 2025-04-22

Family

ID=81346222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562998A Pending JP2024513988A (ja) 2021-04-16 2022-04-13 Ｌｔａ４ｈの阻害剤としてのヘテロアリールアミノプロパノール誘導体

Country Status (13)

Country Link
US (2) US11932630B2 (https=)
EP (2) EP4628163A1 (https=)
JP (1) JP2024513988A (https=)
KR (1) KR20230172533A (https=)
CN (1) CN117015537A (https=)
AU (1) AU2022259056A1 (https=)
BR (1) BR112023019043A2 (https=)
CA (1) CA3210344A1 (https=)
ES (1) ES3049013T3 (https=)
MX (1) MX2023012211A (https=)
PY (1) PY2228191A (https=)
TW (1) TW202304429A (https=)
WO (1) WO2022219546A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI828839B (zh) * 2019-01-11 2024-01-11 瑞士商諾華公司 使用lta4h抑制劑治療化膿性汗腺炎之方法
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CN115785014B (zh) * 2022-12-27 2025-01-24 瑞石生物医药有限公司 四唑衍生物及其用途
CN120365187B (zh) * 2025-04-23 2025-10-10 辽宁众辉生物科技有限公司 一种一锅法合成杀菌剂中间体肟醚的方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500706A (ja) * 2003-07-28 2007-01-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンズイミダゾール、ベンズチアゾールおよびベンゾキサゾール誘導体およびｌｔａ４ｈモジュレーターとしてのそれらの使用
WO2008019306A2 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
WO2008100564A1 (en) * 2007-02-14 2008-08-21 Janssen Pharmaceutica N.V. Lta4h modulators and uses therof
JP2013530180A (ja) * 2010-06-16 2013-07-25 パーデュー、ファーマ、リミテッド、パートナーシップ アリール置換インドールおよびその使用
JP2017505293A (ja) * 2013-12-20 2017-02-16 ノバルティス アーゲー Ｌｔａ４ｈ阻害剤としてのヘテロアリールブタン酸誘導体
WO2017175185A1 (en) * 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2020144604A1 (en) * 2019-01-11 2020-07-16 Novartis Ag Lta4h inhibitors for the treatment of hidradenitis suppurativa
WO2021044351A1 (en) * 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200424183A (en) 2002-08-09 2004-11-16 Nps Pharma Inc New compounds
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP3493359B1 (ja) 2003-03-20 2004-02-03 宣美 辛島 イオン泳動式治療装置
WO2010062829A1 (en) 2008-11-28 2010-06-03 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for treating osteoporosis
JP6080227B2 (ja) 2012-03-06 2017-02-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成を阻害するためのベンゾジオキサン
WO2015009609A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
US11597706B2 (en) 2016-04-18 2023-03-07 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
ES2940611T3 (es) 2016-04-18 2023-05-09 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
RS65492B1 (sr) 2017-07-24 2024-05-31 Novartis Ag Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
CN111094242B (zh) 2017-07-24 2024-02-09 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
EP3669872A4 (en) 2017-08-18 2021-05-05 Shanghai Ennovabio Pharmaceuticals Co., Ltd. FORMYL PYRIDINE DERIVATIVE WITH PD-L1 INHIBITORING EFFECT, MANUFACTURING METHOD FOR IT AND USE THEREOF
EP3697758B1 (en) 2017-10-17 2022-07-06 Novartis AG Sulphonamides and compositions thereof for treating conditions associated with nlrp activity
CN112654350A (zh) 2018-07-03 2021-04-13 诺华股份有限公司 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
US20220267276A1 (en) 2018-07-03 2022-08-25 Novartis Ag Nlrp modulators
EP3817815A1 (en) 2018-07-03 2021-05-12 Novartis AG Nlrp modulators
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
CN112513026B (zh) 2018-07-31 2025-02-25 诺华股份有限公司 Lta4h抑制剂的晶型
TW202028183A (zh) 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
US20220387397A1 (en) 2018-10-24 2022-12-08 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
CN113056451A (zh) 2018-10-24 2021-06-29 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
CR20210235A (es) 2018-11-13 2021-06-30 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
EP3880666B1 (en) 2018-11-13 2023-06-28 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
CN113015730A (zh) 2018-11-13 2021-06-22 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
US20230059136A1 (en) 2018-11-16 2023-02-23 Novartis Ag The compounds and compositions for treating conditions associated with nlrp activity
CN113286784A (zh) 2018-11-16 2021-08-20 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
EP3914583A1 (en) 2019-01-22 2021-12-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
EP3914585A1 (en) 2019-01-23 2021-12-01 Novartis AG Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
JP7545570B2 (ja) 2020-08-14 2024-09-04 ノバルティス アーゲー ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500706A (ja) * 2003-07-28 2007-01-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンズイミダゾール、ベンズチアゾールおよびベンゾキサゾール誘導体およびｌｔａ４ｈモジュレーターとしてのそれらの使用
WO2008019306A2 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
WO2008100564A1 (en) * 2007-02-14 2008-08-21 Janssen Pharmaceutica N.V. Lta4h modulators and uses therof
JP2013530180A (ja) * 2010-06-16 2013-07-25 パーデュー、ファーマ、リミテッド、パートナーシップ アリール置換インドールおよびその使用
JP2017505293A (ja) * 2013-12-20 2017-02-16 ノバルティス アーゲー Ｌｔａ４ｈ阻害剤としてのヘテロアリールブタン酸誘導体
WO2017175185A1 (en) * 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2020144604A1 (en) * 2019-01-11 2020-07-16 Novartis Ag Lta4h inhibitors for the treatment of hidradenitis suppurativa
WO2021044351A1 (en) * 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN MARKERT ET AL.: "Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 4, JPN6025040752, 16 February 2021 (2021-02-16), pages 1889 - 1903, ISSN: 0005703494 *
PAULA B. PAZ ET AL.: "Quantitative structure activity relationship and binding investigation of N-alkyl glycine amides as", MEDICINAL CHEMISTRY RESEARCH, vol. 24, no. 2, JPN6025040753, 17 July 2014 (2014-07-17), pages 496 - 504, ISSN: 0005703495 *

Also Published As

Publication number Publication date
US20220348566A1 (en) 2022-11-03
BR112023019043A2 (pt) 2023-12-05
EP4628163A1 (en) 2025-10-08
CN117015537A (zh) 2023-11-07
AU2022259056A1 (en) 2023-08-31
US11932630B2 (en) 2024-03-19
PY2228191A (es) 2023-09-21
US20240199593A1 (en) 2024-06-20
EP4323062B1 (en) 2025-07-23
EP4323062A1 (en) 2024-02-21
CA3210344A1 (en) 2022-10-20
ES3049013T3 (en) 2025-12-12
WO2022219546A1 (en) 2022-10-20
MX2023012211A (es) 2023-10-26
KR20230172533A (ko) 2023-12-22
TW202304429A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
JP2024513988A (ja) Ｌｔａ４ｈの阻害剤としてのヘテロアリールアミノプロパノール誘導体
TWI864063B (zh) 三環akr1c3依賴性kars抑制劑
JP2024102151A (ja) Ｗｄｒ５タンパク質－タンパク質結合の阻害剤
US20240400518A1 (en) Sos1 inhibitor and use thereof
JP6211530B2 (ja) 含窒素複素環化合物
AU2021237841A1 (en) Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
JP7212763B2 (ja) ＫＥＡＰ１－Ｎｒｆ２タンパク質－タンパク質相互作用の阻害剤
KR20260016466A (ko) Kras(g12d) 단백질의 분해 및 억제를 위한 화합물
CN114269755A (zh) 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物
KR20190117006A (ko) 키나제 억제제로서의 아미노트리아졸로피리딘
JP2021504317A (ja) ハロアリルアミン類のｓｓａｏ／ｖａｐ−１阻害剤とその用途
EP4423068B1 (en) Rxfp1 agonists
TW202233614A (zh) 作為激酶抑制劑之三唑并吡啶化合物
JP5828188B2 (ja) ロイコトリエン産生のオキサジアゾール阻害剤
TW202515851A (zh) Keap1抑制劑及其用途
AU2019387290A1 (en) Pyrazoles as modulators of hemoglobin
CN114650988A (zh) 作为二氢乳清酸脱氢酶(dhodh)抑制剂用于治疗癌症、自身免疫性和炎性疾病的氟化喹啉和喹喔啉衍生物
EA052392B1 (ru) Производные гетероариламинопропанола в качестве ингибиторов lta4h
JP2016108257A (ja) インドリン誘導体
WO2013103150A1 (ja) 置換ピリジン化合物の酸付加塩
WO2016204135A1 (ja) ５員ヘテロ環誘導体
CN121752559A (zh) 吗啉促食欲素受体拮抗剂
WO2026083263A1 (en) (isoquinolin-1-yl)amine derivatives as bfl-1 inhibitors for the treatment of cancer
JP2023552902A (ja) Ｒｈｏ－キナーゼ阻害剤としてのジヒドロフロピリジン誘導体
TW202115023A (zh) 新型細胞凋亡訊號調節激酶1抑制劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260407